Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers

[1]  David T. Gonzales,et al.  A bioinformatics survey for conotoxin-like sequences in three turrid snail venom duct transcriptomes. , 2014, Toxicon : official journal of the International Society on Toxinology.

[2]  G. Visser,et al.  Uptake and transport of superparamagnetic iron oxide nanoparticles through human brain capillary endothelial cells. , 2013, ACS chemical neuroscience.

[3]  J. Droney,et al.  Analgesia and central side-effects: two separate dimensions of morphine response. , 2013, British journal of clinical pharmacology.

[4]  M. Masserini,et al.  Functionalization with TAT-peptide enhances blood-brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-β peptide , 2013 .

[5]  James M. Anderson,et al.  Epithelial barrier assembly requires coordinated activity of multiple domains of the tight junction protein ZO-1 , 2013, Journal of Cell Science.

[6]  J. Zahm,et al.  Rapid method of quantification of tight‐junction organization using image analysis , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[7]  Hye-Won Shin,et al.  Rab11 regulates exocytosis of recycling vesicles at the plasma membrane , 2012, Journal of Cell Science.

[8]  Emanuel Fleige,et al.  Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. , 2012, Advanced drug delivery reviews.

[9]  Vladimir B. Bajic,et al.  Conotoxins that Confer Therapeutic Possibilities , 2012, Marine drugs.

[10]  L. Ren,et al.  Blood–brain barrier transport of Tat peptide and polyethylene glycol decorated gelatin–siloxane nanoparticle , 2012 .

[11]  Nicole F Steinmetz,et al.  Applications of viral nanoparticles in medicine. , 2011, Current opinion in biotechnology.

[12]  Qi Chang,et al.  An in vitro transport model for rapid screening and predicting the permeability of candidate compounds at blood–brain barrier , 2011, Journal of Asian natural products research.

[13]  P. Prevelige,et al.  Genetically programmed in vivo packaging of protein cargo and its controlled release from bacteriophage P22. , 2011, Angewandte Chemie.

[14]  H. Galla,et al.  Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. , 2011, Biochemical and biophysical research communications.

[15]  P. Yu,et al.  The Role of P-Glycoprotein in Transport of Danshensu across the Blood-Brain Barrier , 2011, Evidence-based complementary and alternative medicine : eCAM.

[16]  A. Steiner,et al.  Optimization of oxidative folding methods for cysteine‐rich peptides: a study of conotoxins containing three disulfide bridges , 2011, Journal of peptide science : an official publication of the European Peptide Society.

[17]  N. Puillandre,et al.  The Terebridae and teretoxins: Combining phylogeny and anatomy for concerted discovery of bioactive compounds , 2010, BMC chemical biology.

[18]  T. Nurmikko,et al.  EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision , 2010, European journal of neurology.

[19]  David J Craik,et al.  The engineering of an orally active conotoxin for the treatment of neuropathic pain. , 2010, Angewandte Chemie.

[20]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[21]  Wei Wang,et al.  Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  Reena Halai,et al.  Conotoxins: natural product drug leads. , 2009, Natural product reports.

[23]  Vincent M. Rotello,et al.  Applications of Nanoparticles in Biology , 2008 .

[24]  J. Scherrmann,et al.  CNS Delivery Via Adsorptive Transcytosis , 2008, The AAPS Journal.

[25]  G. Bulaj,et al.  Conus venoms - a rich source of peptide-based therapeutics. , 2008, Current pharmaceutical design.

[26]  D. Luo,et al.  Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. , 2008, Biomaterials.

[27]  B. Zlokovic.  The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[28]  J. Farrar,et al.  Pharmacologic management of neuropathic pain: Evidence-based recommendations , 2007, PAIN.

[29]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[30]  R. Lewis,et al.  Oral absorption and in vivo biodistribution of α-conotoxin MII and a lipidic analogue , 2007 .

[31]  J. McGivern.  Ziconotide: a review of its pharmacology and use in the treatment of pain , 2007, Neuropsychiatric disease and treatment.

[32]  Michelle L Colgrave,et al.  Cyclic MrIA: a stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter. , 2006, Journal of medicinal chemistry.

[33]  Christoph Patsch,et al.  The FASEB Journal Research Communication Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells , 2022 .

[34]  Norelle L Daly,et al.  Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[36]  P. Couraud,et al.  Rat Brain Endothelial Cell Lines for the Study of Blood–Brain Barrier Permeability and Transport Functions , 2005, Cellular and Molecular Neurobiology.

[37]  Miljanich Gp,et al.  Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. , 2004 .

[38]  M. Fromm,et al.  Importance of P-glycoprotein at blood-tissue barriers. , 2004, Trends in pharmacological sciences.

[39]  M. Byas-Smith,et al.  Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. , 2004, JAMA.

[40]  B. Olivera.  Conus Venom Peptides: Reflections from the Biology of Clades and Species , 2002 .

[41]  Acknowledgements , 1992, Experimental Gerontology.

[42]  Katsuya Kato,et al.  A modified colorimetric MTT assay adapted for primary cultured hepatocytes: application to proliferation and cytotoxicity assays. , 1992, Bioscience, biotechnology, and biochemistry.

[43]  J. Heuser,et al.  Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation , 1989, The Journal of cell biology.

[44]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[45]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[46]  R. Lewis.  Conotoxins: molecular and therapeutic targets. , 2009, Progress in molecular and subcellular biology.

[47]  R. Lewis,et al.  Oral absorption and in vivo biodistribution of alpha-conotoxin MII and a lipidic analogue. , 2007, Biochemical and biophysical research communications.

[48]  Miljanich Gp,et al.  Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. , 2004, Current medicinal chemistry.

[49]  B. Olivera,et al.  Conus venoms: a rich source of novel ion channel-targeted peptides. , 2004, Physiological reviews.

[50]  Y. Sai,et al.  Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. , 1997, The Journal of pharmacology and experimental therapeutics.